"Ellen is widely published and an invited speaker on all aspects of breast imaging. She has co-authored the textbook, The Practice of Breast Ultrasound, is a co-organizer of the annual, The Chicago International Breast Course, and serves as the faculty of the International Breast Ultrasound School", said Dr. Rambod and summarized, "Ellen brings outstanding medical, scientific and practical experience along with a passion for the earliest, safest and least costly detection of breast high-risk lesions and cancer". Dr. Mendelson said, "I am pleased and proud to be associated with Quantason in developing a reliable, radiation-free, low-risk, low-cost and accessible automated system to early detect microcalcifications associated with high-risk and carcinoma in situ breast lesions". She concluded that, "in this era of great controversies in breast cancer detection, we are working to enhance our knowledge and experience by adopting new technologies such as IDUSTM which both utilizes the traditional ultrasound systems and significantly improves their performance in providing a robust method for imaging, diagnosis and screening for early detection and follow-up monitoring".
Quantason has developed IDUS™, a revolutionary, next-generation bi-modal platform which fundamentally changes the utilization of conventional ultrasound as a modality for diagnostic imaging and active screening. Quantason's patented and patent-pending technology expands the capabilities of conventional ultrasound systems by combining anatomical 2D imaging with proprietary, real-time stimulation sequences to detect, 3D locate, and classify micron-size target(s) - previously conceived outside of ultrasound capa
Copyright©2012 PR Newswire.
All rights reserved